NASDAQ: KRONKronos Bio Inc Stock
$1.41+0.14 (+11.02%)
Updated Dec 8, 2023
KRON Price
$1.41
Fair Value Price
$2.49
Market Cap
$82.23M
52 Week Low
$0.73
52 Week High
$2.84
P/E
-0.68x
P/B
0.46x
P/S
18.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.00M
Earnings
-$119.14M
Gross Margin
100%
Operating Margin
-2,976.89%
Profit Margin
-2,976.9%
Debt to Equity
0.33
Operating Cash Flow
-$76M
Beta
1.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KRON Overview
Kronos Bio Incorporated is a biopharma developing novel cancer therapeutics. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. The company's lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. It is also developing KB-0742, a bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio was incorporated in 2017 and is headquartered in San Mateo, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KRON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRON ($1.41) is undervalued by 43.34% relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KRON ($1.41) is significantly undervalued by 43.34% relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KRON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRON due diligence checks available for Premium users.
Be the first to know about important KRON news, forecast changes, insider trades & much more!
KRON News
Valuation
KRON fair value
Fair Value of KRON stock based on Discounted Cash Flow (DCF)
Price
$1.41
Fair Value
$2.49
Undervalued by
43.34%
KRON ($1.41) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRON ($1.41) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.68x
Industry
11.7x
Market
31.32x
KRON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
5.42x
KRON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRON's financial health
Profit margin
Revenue
$917.0k
Net Income
-$31.4M
Profit Margin
-3,421.4%
KRON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KRON's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$238.0M
Liabilities
$59.4M
Debt to equity
0.33
KRON's short-term assets ($191.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRON's short-term assets ($191.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.6M
Investing
$35.8M
Financing
$0.0
KRON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KRON vs Biotech Stocks
Kronos Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.